Gene therapy injection aims to restore pigment in Children's eyes
NCT ID NCT07313618
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This early-phase trial tests a single injection of JWK010 gene therapy in 18 children aged 5 to 12 with oculocutaneous albinism type 1 (OCA1), a condition causing little to no pigment in the eyes, skin, and hair. The therapy is designed to help eye cells produce the missing pigment, potentially improving vision and eye structure. The main goal is to check safety, with secondary goals looking at vision changes and pigment restoration.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULOCUTANEOUS ALBINISM (OCA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.